take-away manag meet
crsp climb higher first clinic pt
long sought victori sight move perform
manag increas price target
sno updat support develop strategi vorasidenib
expert call takeaway wilson diseas driver
sell lvmh
analyst certif import disclosur see
long-term incent fee continu free option current
take-away manag meet
recent host meet manag came away increasingli comfort compani growth
profit expect next sever year primari topic investor interest includ recent
announc honey scienc acquisit transit venmo monet gopay acquisit maintain
numer lever grow convers ramp appear quit comfort profit
outlook transit pend acquisit honey scienc improv consumer/merch engag
prove growth/profit accret respect remain encourag venmo growth monet
opportun addit gopay acquisit expand cross-bord potenti chines consum merchant
reiter outperform rate pt
attend meet manag believ stori remain track re-bas benefit set take
effect start roto-root continu perform well attract opportun recent acquisit
addit continu gener strong organ growth trend support strong cash flow compel capit
deploy trend result maintain outperform rate would continu buyer stock furthermor
due increas comfort around reimburs rais price target
crsp climb higher first clinic pt
last week crsp announc result overal result surpass expect patient number two
tdt fairli sever patient transfus annual bl sae occur relat
condit total hb level reach incl hbf surpass bar hb patient ti
month importantli f-cell underlin advantag crispr scd patient four-month follow-up experienc
seven vocs/i bl hbf reach month four beat expect total hb level patient
free voc data preliminari believ warrant read-across ex-vivo project base crsp
abil execut manufactur cell transplant pt
long sought victori sight move perform
mdco agre acquir novarti per share bring long period specul like close
month impress data present inclisiran media report alleg negoti potenti acquir
deal announc bring welcom news mdco investor patient enough weather excit ride
revis model inclisiran reflect asset posit global commerci singl intern
market organ extens geograph reach substanti expertis cardiovascular medicin therebi
increas ex-u revenu forecast elimin royalti arrang previous model mdco
updat drive new price target prior move perform outperform detail full report
manag increas price target
recent attend investor meet new cfo brian newman predecessor richard peretz iro scott
childress consid logic time middl inning transform newman multi-month
exposur peretz view transit progress smoothli appear confid peak season expect
combin solid volum growth enhanc facil autom contribut us domest packag segment
oper margin expans y/i intern effect grown oper profit larg via execut profici
europ manag network global trade trend advanc later inning smart logist
network/transform initi increment garner efficiencies/leverag anticip solid oper margin/ro
perform increas target view peak potenti catalyst
attend meet cfo mark sheahan director busi develop ir david newman topic
span through-the-cycl invest philosophi remain posit near-term demand outlook still
cautiou capit deploy strategi comfort dri powder although target valuat like hinder needle-
move continu expect mute near-term result particularli apac industri limit short-cycl
demand visibl enter therefor look reset earn expect increas confid end-
market stabil and/or pullback share get construct highest-ro name coverag
sno updat support develop strategi vorasidenib glioma
friday societi neuro-oncolog sno annual meet agio present phase result two inhibitor
ivosidenib vorasidenib test periop set low-grad glioma present includ
efficacy-evalu patient patient high-dos vorasidenib cohort achiev object respons
believ updat support agio plan initi phase trial vorasidenib later year clinic profil may
substanti differenti compet idh inhibitor assum pivot indigo trial initi schedul estim
investor may wait least three year data becom avail present success commerci
vorasidenib glioma remain upsid current invest thesi reiter perform
heel givlaari earli approv present updat across rnai therapeut portfolio friday
includ increment perspect onpattro commerci expans well detail relat givlaari upcom launch
potenc toler esc platform highlight support data liver safeti signal
uln yet observ program base technolog also review disciplin approach target select
key criterion genet valid diseas context believ offer substanti de-risk recently-
appoint cfo jeff poulton discuss roi compani anticip path self-sustain reiter
expert call takeaway wilson diseas driver metabol growth
host key opinion leader treatment wilson diseas wd dr peter hedera discuss
treatment landscape/opportun wd dr hedera wd patient treatment new add everi year
highlight call diagnosi rate low often complic heterogen symptom hepat
neurolog misdiagnosi standard care lack signific proport patient paradox afflict
irrevers worsen could potenti address unmet need first-lin therapi wd patient
meanwhil done deep dive wd report attach histor slide wilson therapeut
sell lvmh
earli today lvmh mc-par confirm compani board agre merg transact
valu
all-cash transact expect close
long investor look upon potenti strateg takeout candid
year ago new leadership took helm indic compar prior leader new manag
board member seem much inclin entertain potenti sale brand
view sell lvmh make lot sens compani brand new senior manag perform
well effort strengthen oper control merchandis disciplin compani said result
continu struggl amid region pressur us hong kong stepped-up competit part
better posit global luxuri player much expect lvmh allow continu build brand albeit
back one power influenti team global luxuri good
hard-press envis compet bid emerg indic view fundament valu
like track given on-going pressur detail
sedg host analyst day today expect investor focu potenti addit market share gain
residenti commerci rooftop market time function energi storag product us vs row mix warrant
cost capital-expenditure need energi storag manufactur capac continu believ solar invert market
go longer transit toward mlpe sting invert especi sedg continu drive cost
lower expect sedg also address ip infring battl huawei germani continu believ sedg share
price movement determin time volum margin captur energi storag solut see signific
demand limit avail solut present believ afford sedg opportun captur signific
share solar storag opportun residenti commerci applic
long-term incent fee continu free option current valuat
report gaap ep vs estim consensu estim core basi
exclud neg mark ta cost relat compens adjust
acquisition-rel cost compani report adjust ep vs estim beat primarili driven
lower expens expect despit cash level drop qoq due
cash bonu payout quarter compani still cash debt given strong balanc sheet
continu believ multipl free option drive earn growth longer term
dec cloud summit aw inventla vega nv -- next tuesday
may biotech summit featur chemistri life process institutechicago
